gms | German Medical Science

45. Kongress der Deutschen Gesellschaft für Rheumatologie, 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

06.09. - 09.09.2017, Stuttgart

Investigation of the efficacy and safety of secukinumab treatment in juvenile idiopathic arthritis subtypes of juvenile psoriatic and enthesitis-related arthritis: Design of a randomized, double-blind, placebo controlled, multicenter study

Meeting Abstract

Search Medline for

  • Dirk Föll - Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Klinik für Pädiatrische Rheumatologie und Immunologie, Münster
  • Justyna Veit - Novartis Pharma GmbH, Nürnberg
  • Emma Ilsley - Novartis Pharma AG, Basel, Schweiz
  • Ken Abrams - Novartis Pharmaceuticals Corporation, New Jersey, United States of America

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Stuttgart, 06.-09.09.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocKR.43

doi: 10.3205/17dgrh142, urn:nbn:de:0183-17dgrh1421

Published: September 4, 2017

© 2017 Föll et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Background: Secukinumab (AIN457), an anti-interleukin-17A monoclonal antibody has demonstrated a significant clinically meaningful efficacy on signs and symptoms, structure and function in adults with ankylosing spondylitis (AS) [1] or psoriatic arthritis (PsA) [2], both approved indications. These data support the proposed study in children with ethesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).

This phase 3 study will investigate the efficacy and safety of secukinumab in children ≥ 2 to < 18 years with active JPsA or ERA. The primary objective is to demonstrate that the time to flare in a double-blind placebo control treatment withdrawal part of the trial is longer with secukinumab than placebo.

Methods: Eighty biologic-naïve children with active ERA or JPsA (active: ≥3 active joints and > 1 site of enthesitis at baseline or documented by history) will enroll into treatment period 1 and receive weekly open label s.c. secukinumab 75 or 150 mg, based on their body weight (< 50 kg or ≥ 50 kg) to maintain secukinumab blood levels equivalent to the adult 150mg dose, for the first month then every 4 weeks thereafter. At week 12, responders (minimum JIA ACR Pedi 30 response) enter Treatment period 2 and will be randomized to receive secukinumab or a matching placebo every 4 weeks. Patients enter treatment period 3 if they experience a disease flare or at the end when treatment period 2 closes because target number of flares observed. Upon entering treatment period 3, patients receive open-label secukinumab every 4 weeks until week 100 and then followed until week 112.

Results: The primary efficacy endpoint will be time to flare in treatment period 2. Key secondary endpoints include JIA Pedi ACR 30/50/70/90/100 response rate, total dactylitis and enthesitis counts at week 12. Safety and tolerability will be assessed throughout the study.

Conclusion: The efficacy of Secukinumab in the approved adult indications off PsA or AS support the current study design to evaluate the efficacy and safety of secukinumab treatment in children with active JPsA or ERA.


References

1.
Baeten D, et al. Lancet. 2013;382(9906):1705-13
2.
McInnes IB, et al. Lancet. 2015;386(9999):1137-46.